Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses the role for immunotherapy in patients with a driver mutation.
Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses Liquid...
Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses liquid...
Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses the changing landscape of first-line treatment for EGFR mutation-positive non-small cell lung cancer (NSCLC).
GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there a preferred induction therapy (¿¿Hay alguna terapia de...
Formas de hacer frente a las consecuencias del cuidado de otras personas En esta sección, analizamos posibles medidas que podemos tomar para apoyarnos...
Formas de hacer frente a las consecuencias del cuidado de otras personas En esta sección, analizamos posibles medidas que podemos tomar para apoyarnos...
El apoyo y el cuidador Cuidando a un cuidador Cuando llegan los informes de las pruebas y la creciente expectación confirma los peores temores con un...
El apoyo y el cuidador Cuidando a un cuidador Cuando llegan los informes de las pruebas y la creciente expectación confirma los peores temores con un...
I have seen many posts in which forum members ask where they can purchase various necessary treatments, so I decided to ask you too... Can someone...
Initial dx BAC 2007. New 1.9cm lesion with 5 mm satilite lesion. PET uptake SUV max 10.5 and lymph node L10 suv max5.5. Just had a robotic assisted...
My brother (Dhinesh) and I are caregivers to my mother Mrs. Hemavathi Bai, aged 74, and who has been living with ALK+ lung situation since early 2016...
Hi Grace Members,
Grace is happy to present in partnership with the Swedish Cancer Institute " Local Therapies for Metastatic Lung Cancer Who, What, Why, When and How?" this Saturday, November 10, 2018 | 10:00 am– 1:00 pm Pacific time. This seminar will be available at no charge in person and as a live webinar.
Hello Grace Members,
We are happy to introduce a new partnership with Clinical Care Options to help people better understand treatment options for those just diagnosed with follicular lymphoma. This is the first of several such tools. Other cancer decision making tools CCO will produce in the coming year include decision making tools include early breast cancer and NSCLC.
GRACE has partnered with Clinical Care Options to develop an interactive online tool to help you understand more about your disease and treatment options. Answer a series of multiple-choice questions and then get treatment options chosen by the 5 lymphoma experts listed below.
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
My wife has come a long way with Stage IV lung cancer since 2010. She has now developed acquired resistance to Tarceva.
Gene sequence of biopsy from enlarged pre-vascular and supraclavicular lymph nodes revealed mutation remains EGFR L858R in EXON 21 (original mutation from 2011) and negative to T790M. The cancer is also PD-1 and PD-L1 negative.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
